CU20200048A7 - Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina - Google Patents
Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresinaInfo
- Publication number
- CU20200048A7 CU20200048A7 CU2020000048A CU20200048A CU20200048A7 CU 20200048 A7 CU20200048 A7 CU 20200048A7 CU 2020000048 A CU2020000048 A CU 2020000048A CU 20200048 A CU20200048 A CU 20200048A CU 20200048 A7 CU20200048 A7 CU 20200048A7
- Authority
- CU
- Cuba
- Prior art keywords
- receptor
- triazolobenzazepines
- vasopressin
- antagonists
- refers
- Prior art date
Links
- 102000004136 Vasopressin Receptors Human genes 0.000 title 1
- 108090000643 Vasopressin Receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Abstract
<p>La presente invención se refiere a un de fórmula general (I) útiles en el tratamiento y/o profilaxis de una enfermedad o afección asociada con la función del receptor V1a. Se refiere también a la composición farmacéutica y a una composición combinatoria que comprende este compuesto junto con uno o más principios activos adicionales.</p> <p>(ESPACIO PARA LA FORMULA)</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1700521A HU231206B1 (hu) | 2017-12-15 | 2017-12-15 | Triazolobenzazepinek |
PCT/IB2018/060077 WO2019116324A1 (en) | 2017-12-15 | 2018-12-14 | Triazolobenzazepines as vasopressin v1a receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20200048A7 true CU20200048A7 (es) | 2021-03-11 |
CU24630B1 CU24630B1 (es) | 2022-12-12 |
Family
ID=89992589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2020000048A CU24630B1 (es) | 2017-12-15 | 2018-12-14 | Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina |
Country Status (22)
Country | Link |
---|---|
US (1) | US11298363B2 (es) |
EP (1) | EP3724192B1 (es) |
JP (1) | JP7428647B2 (es) |
KR (1) | KR20200100111A (es) |
CN (1) | CN111479813B (es) |
AR (1) | AR113933A1 (es) |
AU (1) | AU2018385724B2 (es) |
BR (1) | BR112020011880A2 (es) |
CA (1) | CA3085562A1 (es) |
CL (1) | CL2020001564A1 (es) |
CU (1) | CU24630B1 (es) |
EA (1) | EA202091344A1 (es) |
HU (1) | HU231206B1 (es) |
IL (1) | IL275084B2 (es) |
JO (1) | JOP20200149B1 (es) |
MX (1) | MX2020006204A (es) |
PE (1) | PE20210671A1 (es) |
PH (1) | PH12020500548A1 (es) |
SG (1) | SG11202005299VA (es) |
TN (1) | TN2020000083A1 (es) |
TW (1) | TWI826406B (es) |
WO (1) | WO2019116324A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202202495A (zh) | 2020-03-26 | 2022-01-16 | 匈牙利商羅特格登公司 | 作為gamma-胺基丁酸A受體次單元alpha 5受體調節劑之㖠啶及吡啶并〔3,4-c〕嗒𠯤衍生物 |
TWI804119B (zh) * | 2020-12-21 | 2023-06-01 | 大陸商上海濟煜醫藥科技有限公司 | 三氮唑類三并環衍生物及其製備方法和應用 |
HUP2100338A1 (hu) | 2021-09-29 | 2023-04-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
WO2023164710A1 (en) * | 2022-02-28 | 2023-08-31 | The Trustees Of Columbia University In The City Of New York | Avpr1a blockade to reduce social isolation-induced anxiety in females |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0382185B1 (en) | 1989-02-10 | 1994-06-15 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
FR2679903B1 (fr) | 1991-08-02 | 1993-12-03 | Elf Sanofi | Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant. |
US5723606A (en) | 1993-07-21 | 1998-03-03 | Yamanouchi Pharmaceutical Co., Ltd. | Condensed benzazepine derivative and pharmaceutical composition thereof |
MX9606510A (es) | 1994-06-15 | 1997-03-29 | Otsuka Pharma Co Ltd | Derivados benzoheterociclicos. |
FR2740136B1 (fr) | 1995-10-24 | 1998-01-09 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant |
AU2001256769A1 (en) | 2000-05-19 | 2001-11-26 | Merck Patent Gmbh | Triazole derivatives |
WO2002002531A1 (en) | 2000-07-05 | 2002-01-10 | Ortho-Mcneil Pharmaceutical, Inc. | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists |
CA2425892A1 (en) | 2000-11-28 | 2003-04-11 | Hiroyuki Koshio | 1,4,5,6-tetrahydroimidazo[4,5-d]diazepine derivative or salt thereof |
WO2003031407A2 (en) | 2001-10-12 | 2003-04-17 | Serenix Pharmaceuticals, Llc | β-LACTAMYL VASOPRESSIN VlaANTAGONISTS |
JP2005104838A (ja) | 2003-01-09 | 2005-04-21 | Tanabe Seiyaku Co Ltd | 縮合フラン化合物 |
GB0303852D0 (en) * | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
KR100750028B1 (ko) * | 2003-02-19 | 2007-08-16 | 화이자 인코포레이티드 | 치료에 유용한 트리아졸 화합물 |
GB0325021D0 (en) * | 2003-10-27 | 2003-12-03 | Pfizer Ltd | Therapeutic combinations |
OA13347A (en) | 2003-12-22 | 2007-04-13 | Pfizer | Triazole derivatives as vasopressin antagonists. |
GB0400700D0 (en) * | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
EP1632494A1 (en) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
JP2008510789A (ja) | 2004-08-25 | 2008-04-10 | ファイザー・インク | トリアゾロベンゾジアゼピン及びバゾプレシンアンタゴニストとしてのそれらの使用 |
JP2008526702A (ja) | 2004-12-31 | 2008-07-24 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 置換オキシインドール誘導体、該誘導体を含んでいる薬物及びそれらの使用 |
JP2008534461A (ja) | 2005-03-24 | 2008-08-28 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 置換オキシインドール誘導体、前記誘導体を含む医薬およびそれの使用 |
ZA200709626B (en) | 2005-05-13 | 2009-02-25 | Lexicon Pharmaceuticals Inc | Multicyclic compounds and methods of their use |
BRPI0612988A2 (pt) | 2005-07-14 | 2010-12-14 | Hoffmann La Roche | derivados de indol-3-il-carbonil-espiro-piperidina como antagonistas de receptor v1a |
ES2314941T3 (es) | 2005-07-21 | 2009-03-16 | F. Hoffmann-La Roche Ag | Derivados indol-3-il-carbonil-piperidin-benzoimidazol como antagonistas del receptor via. |
BRPI0614692A2 (pt) | 2005-07-29 | 2009-05-19 | Hoffmann La Roche | derivados de indol-3-il-carbonil-piperidina e piperazina |
DE102006051796A1 (de) * | 2006-11-03 | 2008-05-08 | Merck Patent Gmbh | Triaza-benzo[e]azulenderivate |
JP2010517966A (ja) | 2007-02-01 | 2010-05-27 | グラクソ グループ リミテッド | 摂食障害の処置のための1−オキサ−3−アザスピロ(4.5)デカン−2−オンおよび1−オキサ−3,8−ジアザスピロ(4.5)デカン−2−オン誘導体 |
TWI459947B (zh) | 2007-06-26 | 2014-11-11 | Otsuka Pharma Co Ltd | 苯并氮呯化合物及藥學製劑 |
ES2431279T3 (es) | 2008-11-28 | 2013-11-25 | F. Hoffmann-La Roche Ag | Arilciclohexiléteres de dihidro-tetraazabenzoazulenos para uso como antagonistas del receptor V1A de la vasopresina |
GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
TW201103907A (en) | 2009-03-20 | 2011-02-01 | Lundbeck & Co As H | Amide derivatives as neuropeptide Y5 receptor ligands |
SG10201406839VA (en) | 2009-10-26 | 2014-12-30 | Otsuka Pharma Co Ltd | Benzazepine compound |
GB201004677D0 (en) | 2010-03-19 | 2010-05-05 | Vantia Ltd | New salt |
US8461151B2 (en) | 2010-04-13 | 2013-06-11 | Hoffmann-La Roche Inc. | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes |
US8492376B2 (en) | 2010-04-21 | 2013-07-23 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes |
US8513238B2 (en) | 2010-05-10 | 2013-08-20 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes |
TW201206939A (en) | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof |
CN103327980A (zh) * | 2010-11-15 | 2013-09-25 | 艾吉因生物股份有限公司 | 用于治疗认知障碍的苯并二吖庚因衍生物、组合物和方法 |
WO2014048945A1 (de) * | 2012-09-28 | 2014-04-03 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische 5-aryl-triazolo-azepine |
CA2901577A1 (en) | 2013-02-18 | 2014-08-21 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
RS63014B1 (sr) | 2014-12-09 | 2022-04-29 | Bayer Ag | 1,3-tiazol-2-il supstituisani benzamidi |
CN107405333A (zh) | 2015-02-27 | 2017-11-28 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物 |
PL3319959T3 (pl) | 2015-07-06 | 2022-02-14 | Alkermes, Inc. | Hetero-haloinhibitory deacetylazy histonowej |
CN106349241B (zh) * | 2015-07-15 | 2020-04-21 | 上海翰森生物医药科技有限公司 | 具有hsp90抑制活性的三唑衍生物及其制备方法和应用 |
US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
EP3452472A1 (en) | 2016-05-03 | 2019-03-13 | Bayer Aktiengesellschaft | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof |
WO2017191107A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Amide-substituted phenyltriazole derivatives and uses thereof |
-
2017
- 2017-12-15 HU HU1700521A patent/HU231206B1/hu unknown
-
2018
- 2018-12-12 TW TW107144774A patent/TWI826406B/zh active
- 2018-12-13 AR ARP180103643A patent/AR113933A1/es unknown
- 2018-12-14 PE PE2020000640A patent/PE20210671A1/es unknown
- 2018-12-14 KR KR1020207020172A patent/KR20200100111A/ko not_active Application Discontinuation
- 2018-12-14 CU CU2020000048A patent/CU24630B1/es unknown
- 2018-12-14 TN TNP/2020/000083A patent/TN2020000083A1/en unknown
- 2018-12-14 SG SG11202005299VA patent/SG11202005299VA/en unknown
- 2018-12-14 AU AU2018385724A patent/AU2018385724B2/en active Active
- 2018-12-14 EP EP18836400.4A patent/EP3724192B1/en active Active
- 2018-12-14 JP JP2020532928A patent/JP7428647B2/ja active Active
- 2018-12-14 WO PCT/IB2018/060077 patent/WO2019116324A1/en active Application Filing
- 2018-12-14 EA EA202091344A patent/EA202091344A1/ru unknown
- 2018-12-14 JO JOP/2020/0149A patent/JOP20200149B1/ar active
- 2018-12-14 MX MX2020006204A patent/MX2020006204A/es unknown
- 2018-12-14 US US16/954,085 patent/US11298363B2/en active Active
- 2018-12-14 CA CA3085562A patent/CA3085562A1/en active Pending
- 2018-12-14 CN CN201880080932.8A patent/CN111479813B/zh active Active
- 2018-12-14 BR BR112020011880-0A patent/BR112020011880A2/pt unknown
-
2020
- 2020-06-03 IL IL275084A patent/IL275084B2/en unknown
- 2020-06-09 PH PH12020500548A patent/PH12020500548A1/en unknown
- 2020-06-11 CL CL2020001564A patent/CL2020001564A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TWI826406B (zh) | 2023-12-21 |
BR112020011880A2 (pt) | 2020-11-24 |
KR20200100111A (ko) | 2020-08-25 |
JP7428647B2 (ja) | 2024-02-06 |
CN111479813A (zh) | 2020-07-31 |
AR113933A1 (es) | 2020-07-01 |
EA202091344A1 (ru) | 2020-09-09 |
PH12020500548A1 (en) | 2021-01-25 |
HU231206B1 (hu) | 2021-10-28 |
JOP20200149B1 (ar) | 2022-10-30 |
TN2020000083A1 (en) | 2022-01-06 |
JOP20200149A1 (ar) | 2020-06-10 |
SG11202005299VA (en) | 2020-07-29 |
AU2018385724B2 (en) | 2023-05-25 |
TW201938170A (zh) | 2019-10-01 |
PE20210671A1 (es) | 2021-04-05 |
US11298363B2 (en) | 2022-04-12 |
US20210260072A1 (en) | 2021-08-26 |
EP3724192B1 (en) | 2022-08-03 |
AU2018385724A1 (en) | 2020-07-09 |
HUP1700521A2 (en) | 2019-06-28 |
CA3085562A1 (en) | 2019-06-20 |
CN111479813B (zh) | 2023-03-21 |
EP3724192A1 (en) | 2020-10-21 |
JP2021506821A (ja) | 2021-02-22 |
CU24630B1 (es) | 2022-12-12 |
CL2020001564A1 (es) | 2020-11-06 |
IL275084A (en) | 2020-07-30 |
IL275084B2 (en) | 2023-06-01 |
MX2020006204A (es) | 2020-08-27 |
WO2019116324A1 (en) | 2019-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20200048A7 (es) | Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina | |
CL2017001362A1 (es) | Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática | |
CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
CL2018000953A1 (es) | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) | |
CL2018001705A1 (es) | Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante. | |
CL2018001478A1 (es) | Agonistas del receptor de apelina y métodos de uso | |
CO2018007221A2 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) | |
CL2018002671A1 (es) | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj) | |
CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
SV2016005180A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
CU24397B1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b | |
GT201600215A (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
CL2015001864A1 (es) | Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih. | |
NI201800075A (es) | Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos. | |
CU20160111A7 (es) | Compuestos de heterociclilo bicíclico como inhibidores de irak4 | |
CO2020007156A2 (es) | Derivado de amino-metil piperidina como inhibidor de quinasa | |
DOP2020000109A (es) | Derivado de amino-flocoropiperidina como inhibidor de quinasa | |
CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
CL2013002898A1 (es) | Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer. | |
CL2017001650A1 (es) | Derivados de 5-[(piperazina-1-yl)-3-oxo-propilo]-imidazolidina-2,4-dionan como inhibidores adamts para el tratamiento oesteoartritis. | |
CL2020001394A1 (es) | Combinación de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina. | |
CO2020007162A2 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
GT201500247A (es) | Imidazopiridazinas sustituidas | |
EA201990159A1 (ru) | Биарилметильные гетероциклы | |
AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 |